Maximus, Inc. (MMS) Position Raised by First Midwest Bank Trust Division
First Midwest Bank Trust Division increased its stake in shares of Maximus, Inc. (NYSE:MMS) by 2.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,265 shares of the health services provider’s stock after buying an additional 465 shares during the period. First Midwest Bank Trust Division’s holdings in Maximus were worth $1,269,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of MMS. Neuburgh Advisers LLC increased its stake in Maximus by 1.9% in the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock valued at $105,000 after buying an additional 32 shares in the last quarter. Acrospire Investment Management LLC increased its stake in Maximus by 183.3% in the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $106,000 after buying an additional 1,100 shares in the last quarter. Glen Harbor Capital Management LLC increased its stake in Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock valued at $145,000 after buying an additional 44 shares in the last quarter. Elkfork Partners LLC increased its stake in Maximus by 1.9% in the first quarter. Elkfork Partners LLC now owns 2,968 shares of the health services provider’s stock valued at $185,000 after buying an additional 56 shares in the last quarter. Finally, Violich Capital Management Inc. bought a new stake in Maximus during the first quarter valued at $217,000. 97.89% of the stock is owned by hedge funds and other institutional investors.
Shares of Maximus, Inc. (NYSE MMS) opened at 61.06 on Monday. Maximus, Inc. has a one year low of $43.69 and a one year high of $64.97. The stock has a market capitalization of $3.96 billion, a price-to-earnings ratio of 20.02 and a beta of 1.39. The stock’s 50 day moving average is $61.91 and its 200-day moving average is $60.73.
Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The firm had revenue of $600.40 million for the quarter, compared to analyst estimates of $614.12 million. During the same period last year, the business earned $0.79 EPS. Maximus’s revenue for the quarter was down 2.7% compared to the same quarter last year. On average, equities research analysts predict that Maximus, Inc. will post $3.09 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Investors of record on Tuesday, August 15th will be paid a dividend of $0.045 per share. The ex-dividend date is Friday, August 11th. This represents a $0.18 annualized dividend and a yield of 0.29%. Maximus’s dividend payout ratio is currently 5.73%.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/07/maximus-inc-mms-stake-increased-by-first-midwest-bank-trust-division-updated.html.
Several research firms have recently weighed in on MMS. BidaskClub downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Maxim Group set a $66.00 price objective on shares of Maximus and gave the stock a “hold” rating in a research note on Thursday. ValuEngine downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. KeyCorp reissued a “sector weight” rating on shares of Maximus in a research note on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. Maximus presently has an average rating of “Hold” and a consensus price target of $62.17.
In other Maximus news, President Bruce Caswell sold 17,197 shares of the firm’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $62.47, for a total transaction of $1,074,296.59. Following the transaction, the president now directly owns 27,904 shares of the company’s stock, valued at approximately $1,743,162.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David Francis sold 1,000 shares of the firm’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $60.46, for a total transaction of $60,460.00. Following the transaction, the general counsel now directly owns 15,715 shares in the company, valued at $950,128.90. The disclosure for this sale can be found here. Insiders have sold a total of 117,846 shares of company stock worth $7,381,746 over the last quarter. 3.10% of the stock is owned by company insiders.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Stock Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related stocks with our FREE daily email newsletter.